Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

BACKGROUND AND OBJECTIVES: The oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. METHODS: In this phase 3, 12-week, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Pozo-Rosich, Patricia, Blumenfeld, Andrew M., Li, Ye, Severt, Lawrence, Stokes, Jonathan T., Creutz, Lela, Gandhi, Pranav, Dodick, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984220/
https://www.ncbi.nlm.nih.gov/pubmed/36396451
http://dx.doi.org/10.1212/WNL.0000000000201568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984220/
https://www.ncbi.nlm.nih.gov/pubmed/36396451
http://dx.doi.org/10.1212/WNL.0000000000201568

Ejemplares similares